StreetInsider.com News Articles

RBC Capital on Bristol-Myers Squibb Co. (BMY): 'Strong Execution Expected But May be Overshadowed by Key Binary Catalyst'

Mon, 19 Oct 2026 09:28:58 -0400

RBC Capital analyst Trung Huynh reiterated a Sector Perform rating and $64.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).

The analyst commented: "3Q26 Preview: Strong Execution Expected But May be Overshadowed by Key Binary Catalysts; We're ahead of consensus on the top-line (+2%), and ~1% ahead on EPS (ex-IPR&D, which is not up-to-date). We see outperformance driven by legacy products Eliquis (+1%) and Revlimid (+29%) but also growth drivers Qvantig (+4%), Breyanzi (+6%), Opdualag (+5%), Camzyos (+4%), Reblozyl (+3%), and Sotyktu (+8%). However, we think results will matter less for 3Q26 as we get closer to milvexian data (SSP and

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

Mon, 19 Oct 2026 06:59:00 -0400

Late-breaking Phase 3 disclosures for izalontamab brengitecan (iza-bren), a potential first-in-class EGFR × HER3 bispecific ADC, in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01)

Late-breaking Phase 2 global data presentation for pumitamig, a PD-L1 × VEGF-A bispecific immunomodulator, from ROSETTA Lung-107 in metastatic non-small cell lung cancer

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced it will present new data from its oncology portfolio and pipeline across a broad range of solid tumors at the European Society for Medical Oncology (ESMO) 2026 Congress to be held October

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

Mon, 19 Oct 2026 06:59:00 -0400

Late-breaking Phase 2 global data presentation for pumitamig, a PD-L1 × VEGF-A bispecific immunomodulator, from ROSETTA Lung-107 in metastatic non-small cell lung cancer

Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at HSBC

Mon, 19 Oct 2026 01:32:00 -0400

HSBC analyst Rajesh Kumar lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $60.00 (from $65.00) while maintaining a Hold rating.

Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Stock remains constrained by questions & remaining catalyst pathway'

Tue, 13 Oct 2026 08:59:58 -0400

Bernstein SocGen Group analyst Courtney Breen reiterated a Market Perform rating and $61.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).

The analyst commented: "IPF endpoint met... stock remains constrained by questions & remaining catalyst pathway; Today’s data: While the Admilparant data that PR’d today was technically positive, we note that from current disclosures there appears to be no dose-response (60mg successful, 120mg not successful- despite greater alpha-allocation in the statistical plan), the language in the press release of “met primary endpoint” made no reference to clinical meaningfulness & the liver-toxicity questions have not been validated yet with any disclosures of

Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at Wells Fargo

Tue, 13 Oct 2026 05:55:42 -0400

Wells Fargo analyst Mohit Bansal lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $60.00 (from $65.00) while maintaining a Equal Weight rating.

The analyst comments "Mgmt on upcoming LOEs and growth products. On Eliquis, mgmt reaffirmed their current guidance but noted, for OUS/US mix, Eliquis' LOE is in mid-November for some big EU markets, and they expect a rapid decline afterward. On the growth portfolio, mgmt noted Breyanzi growth remains strong, and 3Q seasonality may be less than anticipated. For Opdivo, mgmt reaffirmed the $200M in sequential inventory build in 2Q that is expected to partially or fully

Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at Wells Fargo

Tue, 13 Oct 2026 05:55:42 -0400

Wells Fargo analyst Mohit Bansal lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $60.00 (from $65.00) while maintaining a Equal Weight rating.

Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes

Mon, 12 Oct 2026 07:27:27 -0400

Investing.com -- Bristol Myers Squibb (NYSE: BMY) shares surged 6.5% on Monday following the announcement of positive top-line results from two separate Phase 3 clinical trials evaluating targeted therapies for neuroendocrine tumors and idiopathic pulmonary fibrosis. [pro_promotion |

Unlock key market insights by upgrading to InvestingPro. Get 50% off today!

]]

ACTION-1 Trial Demonstrates Significant PFS Improvement in GEP-NETs

The pivotal ACTION-1 trial evaluating RYZ101 (225Ac-DOTATATE) met

Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes

Mon, 12 Oct 2026 07:27:27 -0400

Unlock key market insights by upgrading to InvestingPro. Get 50% off today!

]]

ACTION-1 Trial Demonstrates Significant PFS Improvement in GEP-NETs

The pivotal ACTION-1 trial evaluating RYZ101 (225Ac-DOTATATE) met

Bristol Myers Squibb's RYZ101 meets primary endpoint in phase 3 GEP-NET trial

Mon, 12 Oct 2026 06:55:20 -0400

Bristol Myers Squibb (NYSE: BMY) announced that its investigational radiopharmaceutical RYZ101 met the primary endpoint in the planned interim analysis of the Phase 3 ACTION-1 trial, showing a statistically significant improvement in progression-free survival in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The trial evaluated RYZ101, developed by RayzeBio, a Bristol Myers Squibb company, against investigator's choice of standard-of-care treatments in patients whose cancer had progressed following Lutetium-177-based therapy. Safety results were described as consistent with the known RYZ101 profile.

RYZ101 is comprised of DOTATATE bound to Actinium-225, an alpha-emitting radioisotope. According to the company, these are the first Phase 3

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

Mon, 12 Oct 2026 06:55:00 -0400

The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression free survival (PFS)

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review, and safety results consistent with the known RYZ101 safety profile. ACTION-1 is a randomized Phase 3

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

Mon, 12 Oct 2026 06:55:00 -0400

The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression free survival (PFS)

Bristol Myers Squibb lung fibrosis drug meets Phase 3 trial goal

Mon, 12 Oct 2026 06:50:18 -0400

Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis (IPF) met its primary endpoint at the 60 mg dose.

The trial showed a statistically significant improvement in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placebo for the 60 mg twice-daily dose. The 120 mg dose slowed FVC decline but did not reach statistical significance. The trial enrolled approximately 1,255 adults aged 40 and older and compared two dose levels against placebo in a 1:1:1 ratio.

Admilparant is an orally administered lysophosphatidic acid receptor 1

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Mon, 12 Oct 2026 06:50:00 -0400

In the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placebo

Admilparant demonstrated a favorable safety and tolerability profile

The totality of the findings supports the potential of admilparant as a clinically meaningful first-in-class treatment

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant, a potential first-in-class, orally administered, potent and selective lysophosphatidic acid receptor 1

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Mon, 12 Oct 2026 06:50:00 -0400

In the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placebo

Admilparant demonstrated a favorable safety and tolerability profile

The totality of the findings supports the potential of admilparant as a clinically meaningful first-in-class treatment

Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Cantor Fitzgerald on Anticipated Milvexian Pressure

Thu, 08 Oct 2026 07:12:56 -0400

Cantor Fitzgerald analyst Carter Gould lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $59.00) while maintaining a Neutral rating.

The analyst commented, "Admilparant and milvexian continue to dictate the setup over near-term earnings. We're modestly positively biased into the admilparant read-out. From there, however, we expect either continued or renewed pressure on BMY shares as investors then focus on milvexian."

Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Cantor Fitzgerald on Anticipated Milvexian Pressure

Thu, 08 Oct 2026 07:12:56 -0400

Cantor Fitzgerald analyst Carter Gould lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $59.00) while maintaining a Neutral rating.

BMS drug Zenbexus cuts myeloma progression risk by 51% in trial

Thu, 08 Oct 2026 06:59:21 -0400

Bristol Myers Squibb (NYSE: BMY) announced positive topline results from its Phase 3 EXCALIBER-RRMM study, showing that Zenbexus (iberdomide) combined with daratumumab and dexamethasone (ZDd) significantly reduced the risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

The study, which enrolled 800 patients with multiple myeloma as early as first relapse, showed a median progression-free survival (PFS) of 42 months for the ZDd regimen compared with 20 months for the daratumumab, bortezomib and dexamethasone (DVd) regimen. The hazard ratio was 0.49 (p<0.000001), representing a 51% reduction in the risk of disease progression or death. Median follow-up

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refr

Thu, 08 Oct 2026 06:59:00 -0400

In the EXCALIBER study, results showed a progression-free survival hazard ratio of 0.49 compared with daratumumab, bortezomib and dexamethasone

PRINCETON, N.J.--(BUSINESS WIRE)--

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3 EXCALIBER-RRMM Study

Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the Phase 3 EXCALIBER-RRMM study, evaluating ZENBEXUSTM (iberdomide) in combination with daratumumab and dexamethasone (ZDd) in 800 patients with multiple myeloma (MM), as early as first relapse.

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refr

Thu, 08 Oct 2026 06:59:00 -0400

In the EXCALIBER study, results showed a progression-free survival hazard ratio of 0.49 compared with daratumumab, bortezomib and dexamethasone

PRINCETON, N.J.--(BUSINESS WIRE)--

Bristol-Myers Squibb Co. (BMY) PT Raised to $41 at Morgan Stanley

Wed, 07 Oct 2026 07:58:19 -0400

Morgan Stanley analyst Matthew Harrison raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $41.00 (from $40.00) while maintaining a Underweight rating.

Form 4 BRISTOL MYERS SQUIBB CO For: Oct 02 Filed by: Gallman Cari

Mon, 05 Oct 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20261005/27149028.html

Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt

Mon, 05 Oct 2026 09:30:44 -0400

Investing.com -- Shares of Bristol-Myers Squibb Co. (NYSE: BMY) fell 2.5% in premarket trading after Leerink Partners downgraded the pharmaceutical giant from Outperform to Market Perform, citing growing skepticism surrounding key candidates in the company’s drug development pipeline.

Alongside the downgrade, Leerink slashed its price target on the stock to $59 from $73. Analyst David Risinger emphasized that upcoming clinical readouts pose significant risks, leaving the firm without the confidence needed to recommend the stock.

"We changed our investment thesis after conducting more detailed assessments of key pipeline candidates reading out over the next several

Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt

Mon, 05 Oct 2026 09:30:44 -0400

"We changed our investment thesis after conducting more detailed assessments of key pipeline candidates reading out over the next several

Leerink Downgrades Bristol-Myers Squibb Co. (BMY) to Market Perform

Mon, 05 Oct 2026 07:59:41 -0400

Leerink analyst David Risinger downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Outperform to Market Perform with a price target of $59.00.

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $61.15 yesterday.